DirectorsTalk Interviews cover art

DirectorsTalk Interviews

DirectorsTalk Interviews

By: DirectorsTalk
Listen for free

DirectorsTalk Interviews focus on financial markets and investment opportunities. The site features interviews with company directors, market analysts, and experts, offering insights into companies' performance, industry trends, and market updates. The content includes Q&A sessions, market commentary, and discussions about business developments, often highlighting the viewpoints of executives from publicly traded companies.DirectorsTalk Economics Personal Finance
Episodes
  • RM Plc Assessment Pipeline Doubles as RM Ava Opens New Growth Markets
    Jul 17 2026

    RM Plc (LON:RM) Chief Financial Officer Simon Goodwin explains how accelerating demand for secure digital examinations, a doubled sales pipeline and a 100% first-half contract renewal rate are strengthening the group’s Assessment division. He also outlines how the £20 million RM Ava investment could expand RM’s reach into professional qualifications and government-regulated testing, while further cost savings and operational separation support the group’s full-year profit expectations.

    Key Moments

    • 00:09 — What is driving Assessment’s growth
    • 01:08 — Contract renewals reach 100%
    • 01:22 — The sales pipeline doubles
    • 02:00 — Inside the £20 million RM Ava investment
    • 02:22 — Scaling to millions of candidates
    • 03:05 — Where further efficiencies can be found
    • 03:50 — More than £3 million of further savings targeted
    • 03:59 — What Technology and TTS need to return to growth
    • 05:31 — The biggest drivers of full-year performance
    • 06:13 — Profit and EBITDA expectations remain on track


    RM Plc is an education technology and resources group operating through Assessment, Technology and TTS. The company provides digital assessment platforms and services, technology solutions for schools, and educational products used by teachers and learners in the UK and internationally.

    Show More Show Less
    7 mins
  • James Cropper plc Lifts EBITDA 33% as Debt Falls Below One Times Earnings
    Jul 16 2026

    James Cropper plc (LON:CRPR) has delivered a sharp improvement in profitability while strengthening its balance sheet and restoring momentum in paper and packaging. CEO David Stirling explains how adjusted EBITDA rose from £6.7 million to £8.9 million, nearly £5 million of debt was repaid and advanced materials achieved 11% growth, while setting out where the next phase of growth could come from.

    Key Moments

    • 00:19 – EBITDA jumps 33% as revenue rises 4%
    • 00:37 – Nearly £5 million of debt repaid
    • 01:02 – The three priorities reshaping James Cropper
    • 01:18 – Advanced materials delivers 11% growth
    • 01:42 – Paper and packaging fights back after losing a major customer
    • 02:02 – Second-half profitability builds momentum
    • 02:16 – Tighter capital discipline strengthens the balance sheet
    • 02:42 – What drove record advanced materials revenue
    • 03:22 – How cost cuts returned paper and packaging to profitability
    • 04:03 – Where management sees the next growth drivers
    • 04:24 – Refinancing puts the group on firmer footing


    James Cropper plc is a specialist materials group operating across advanced materials, paper and luxury packaging. The company develops high-performance materials and specialist paper products for customers across sectors including aerospace, renewable energy, luxury goods and technical applications.

    Show More Show Less
    5 mins
  • EDX Medical Group Targets More Than £2 Million From New Employee Health Screening Service
    Jul 16 2026

    Sir Chris Evans explains why EDX Medical Group (LON:EDX) believes its new workplace health screening service can generate more than £2 million in the current financial year, with employers already discussing programmes covering thousands of staff. He outlines how the company combines rapid on-site sample collection, multi-biomarker testing and personalised health reports to identify risks earlier, reduce disruption and potentially lower the cost of employee ill health.

    Key Moments

    • 00:19 – Inside EDX Medical’s rapid workplace screening model
    • 01:20 – How EDX’s biomarker panels scan for hundreds of conditions
    • 02:22 – Why EDX says its service outperforms rivals
    • 04:18 – The employer demand behind the £2 million revenue target
    • 05:16 – Fresh interest from major employers after launch
    • 06:10 – The multibillion-pound cost of workplace ill health
    • 07:25 – Why better screening could boost loyalty and productivity
    • 07:49 – The follow-up testing strategy EDX has yet to reveal
    • 09:02 – The contract and revenue updates investors could see next


    EDX Medical Group develops diagnostic products and services designed to detect disease risks earlier and support more personalised healthcare decisions. Its work includes advanced biomarker testing, genomic analysis and digitally supported screening services for individuals, clinicians and employers.

    Show More Show Less
    11 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet